JAK inhibitors in rheumatology: implications for paediatric syndromes?

Kerrigan, S.A. and McInnes, I.B. (2018) JAK inhibitors in rheumatology: implications for paediatric syndromes? Current Rheumatology Reports, 20(12), 83. (doi: 10.1007/s11926-018-0792-7) (PMID:30406861) (PMCID:PMC6223710)

171336.pdf - Published Version
Available under License Creative Commons Attribution.



Purpose of Review: Given the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients. Recent Findings: Significant advances have been made in the management of rheumatic diseases in the past two decades. The introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment options. Summary: Since 2012, Janus kinase (JAK) inhibitors (JAKinibs), a novel group of oral small molecule inhibitors, have demonstrated their efficacy in several forms of adult inflammatory arthritis, such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA). There are hopes that these successes will be transferable to the paediatric population. In the following review, we discuss the development and progress of JAKinibs in this regard.

Item Type:Articles
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Kerrigan, Dr Sean
Authors: Kerrigan, S.A., and McInnes, I.B.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Current Rheumatology Reports
ISSN (Online):1534-6307
Published Online:08 November 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Current Rheumatology Reports 20(12): 83
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record